EGFR and breast carcinoma: While resistance mechanisms have been reported for anti-EGFR/HER2 therapies in HER2-overexpressing breast cancer [14, 15] and other cancers [16, 17], the reason for the lack of efficacy of EGFR and EGFR/HER2 inhibitors in TNBC remains unknown.